Baxter (BAX) Tops Q2 EPS by 6c; Guides
Get Alerts BAX Hot Sheet
EPS Growth %: +3.4%
Financial Fact:
Other expense, net: 44M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Baxter (NYSE: BAX) reported Q2 EPS of $0.80, $0.06 better than the analyst estimate of $0.74. Revenue for the quarter came in at $3.1 billion versus the consensus estimate of $3.11 billion.
“As markets worldwide continue to cope with the effects from the COVID-19 pandemic, Baxter’s second quarter performance reflects the diversity and durability of our lifesaving portfolio combined with the breadth of our geographic reach,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “Our drive to innovate, the essential nature of our product lines and the momentum of our transformation are all critical factors in our effort to improve performance and extend our impact. I am looking forward to our upcoming Investor Conference in September, where we will showcase our strategies to help drive incremental value for patients, clinicians, investors and the many other stakeholders we serve.”
GUIDANCE:
Baxter sees FY2021 EPS of $3.49-$3.55, versus the consensus of $3.51.
For earnings history and earnings-related data on Baxter (BAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Utah Medical Products (UTMD) Reports Q1 EPS of $1.10
- Allison Transmission (ALSN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY24 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!